# LB Pharmaceuticals Inc: financial statements, quarterly

LBRX · Nasdaq · CIK 1691082 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lbrx.md) · [Financials](/companies/lbrx/financials.md) · [Filings](/companies/lbrx/filings.md) · [Insiders](/companies/lbrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lbrx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | [10.7](/filings/0001193125-25-268174.md) | [0.4 d](/filings/0001193125-26-126368.md) | [3.4](/filings/0001193125-26-219607.md) | [2.4](/filings/0001193125-26-343490.md) | [2.4](/filings/0001193125-25-268174.md) | [8.5 d](/filings/0001193125-26-126368.md) | [14.6](/filings/0001193125-26-219607.md) | [44.1](/filings/0001193125-26-343490.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001193125-25-268174.md) | [0.0 d](/filings/0001193125-26-126368.md) | [0.0](/filings/0001193125-26-219607.md) | [0.0](/filings/0001193125-26-343490.md) | [0.0](/filings/0001193125-25-268174.md) | [0.0 d](/filings/0001193125-26-126368.md) | [0.0](/filings/0001193125-26-219607.md) | [0.0](/filings/0001193125-26-343490.md) |
| Net income | $m | [(16.2)](/filings/0001193125-25-268174.md) | [(27.6)](/filings/0001193125-25-268174.md) | [(14.2)](/filings/0001193125-25-268174.md) | [(5.1) d](/filings/0001193125-26-126368.md) | [(5.3)](/filings/0001193125-26-343490.md) | [(4.9)](/filings/0001193125-26-343490.md) | [(3.6)](/filings/0001193125-25-268174.md) | [(11.5) d](/filings/0001193125-26-126368.md) | [(19.1)](/filings/0001193125-26-343490.md) | [(51.6)](/filings/0001193125-26-343490.md) |
| Diluted EPS | $ per share | not reported | not reported | [(39.49)](/filings/0001193125-25-268174.md) | not reported | [(14.79)](/filings/0001193125-26-219607.md) | [(13.58)](/filings/0001193125-26-343490.md) | [(0.61)](/filings/0001193125-25-268174.md) | not reported | [(0.67)](/filings/0001193125-26-219607.md) | [(1.71)](/filings/0001193125-26-343490.md) |
| Basic EPS | $ per share | not reported | not reported | [(39.49)](/filings/0001193125-25-268174.md) | not reported | [(14.79)](/filings/0001193125-26-219607.md) | [(13.58)](/filings/0001193125-26-343490.md) | [(0.61)](/filings/0001193125-25-268174.md) | not reported | [(0.67)](/filings/0001193125-26-219607.md) | [(1.71)](/filings/0001193125-26-343490.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [23.0](/filings/0001193125-26-126368.md) | not reported | not reported | [270](/filings/0001193125-25-268174.md) | [250](/filings/0001193125-26-343490.md) | [321](/filings/0001193125-26-219607.md) | [283](/filings/0001193125-26-343490.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [28.9](/filings/0001193125-26-126368.md) | not reported | not reported | [316](/filings/0001193125-25-268174.md) | [308](/filings/0001193125-26-343490.md) | [389](/filings/0001193125-26-219607.md) | [355](/filings/0001193125-26-343490.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [33.5](/filings/0001193125-26-126368.md) | not reported | not reported | [321](/filings/0001193125-25-268174.md) | [313](/filings/0001193125-26-343490.md) | [393](/filings/0001193125-26-219607.md) | [362](/filings/0001193125-26-343490.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [8.1](/filings/0001193125-26-126368.md) | not reported | not reported | [6.6](/filings/0001193125-25-268174.md) | [7.4](/filings/0001193125-26-343490.md) | [10.9](/filings/0001193125-26-219607.md) | [23.6](/filings/0001193125-26-343490.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [13.8](/filings/0001193125-26-126368.md) | not reported | not reported | [10.5](/filings/0001193125-25-268174.md) | [11.6](/filings/0001193125-26-343490.md) | [14.8](/filings/0001193125-26-219607.md) | [29.3](/filings/0001193125-26-343490.md) |
| Shareholders' equity | $m | [(34.5)](/filings/0001193125-26-126368.md) | [(50.4)](/filings/0001193125-25-268174.md) | [(77.4)](/filings/0001193125-25-268174.md) | [(91.5)](/filings/0001193125-25-268174.md) | [(94.6)](/filings/0001193125-26-343490.md) | [(99.3)](/filings/0001193125-26-343490.md) | [(104)](/filings/0001193125-26-343490.md) | [310](/filings/0001193125-25-268174.md) | [301](/filings/0001193125-26-343490.md) | [379](/filings/0001193125-26-343490.md) | [332](/filings/0001193125-26-343490.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.7) d](/filings/0001193125-26-126368.md) | [(8.1)](/filings/0001193125-26-219607.md) | [(5.6) d](/filings/0001193125-26-343490.md) | [(3.4) d](/filings/0001193125-25-268174.md) | [(18.1) d](/filings/0001193125-26-126368.md) | [(23.3)](/filings/0001193125-26-219607.md) | [(37.6) d](/filings/0001193125-26-343490.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001193125-26-126368.md) | [0.0](/filings/0001193125-26-219607.md) | [(0.0) d](/filings/0001193125-26-343490.md) | [0.0 d](/filings/0001193125-25-268174.md) | [0.0 d](/filings/0001193125-26-126368.md) | [0.0](/filings/0001193125-26-219607.md) | [0.4 d](/filings/0001193125-26-343490.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.4](/filings/0001193125-25-268174.md) | [0.4](/filings/0001193125-26-219607.md) | [0.4](/filings/0001193125-26-343490.md) | [5.8](/filings/0001193125-25-268174.md) | [28.2](/filings/0001193125-26-219607.md) | [30.1](/filings/0001193125-26-343490.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,259,175 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343490.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.